Close Menu

Alnylam and Medtronic are working together to develop RNA interference as a treatment for Huntington's disease, reports The Wall Street Journal. Medtronic is working the task of creating a pump and catheter system to deliver Alnylam's therapy to the right spot of the brain "without hiking up cranial pressure too much and damaging brain tissue," the Journal adds. Alnylam is using an siRNA to block mRNA.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.